SB Samsung Biologics 207940 · KRX · Healthcare
OpenDART ↗ OpenDART Filings checked 23 Oct 2026, 17:19 UTC Financials checked 23 Oct 2026, 17:19 UTC
Some records were last checked more than 24 hours ago. These are the last verified records; check the official source for the latest filings.
Annual reporting period: 2025-01-01 — 2025-12-31 · KRW
Annual revenue ₩4.56T Year over year +0.2%
Annual net income ₩1.78T Consolidated net income
Annual operating income ₩2.07T Consolidated basis
Operating margin 45.4% Operating income / revenue
Revenue over time ANNUAL
2021-12-31 · 1,568,006,928,039 KRW
2021 ₩1.57T
2022-12-31 · 3,001,295,197,683 KRW
2022 ₩3T
2023-12-31 · 3,694,588,767,068 KRW
2023 ₩3.69T
2024-12-31 · 4,547,322,176,421 KRW
2024 ₩4.55T
2025-12-31 · 4,556,971,695,180 KRW
2025 ₩4.56T Each bar is one fiscal year of revenue, ending on the date shown.
Income statement CONSOLIDATED Line 2025 2024 2023 2022 2021 Revenue ₩4.56T ₩4.55T ₩3.69T ₩3T ₩1.57T Cost of revenue ₩2.04T ₩2.26T ₩1.89T ₩1.53T ₩841.56B Gross profit ₩2.52T ₩2.29T ₩1.8T ₩1.47T ₩726.45B Selling, general and administrative ₩447.42B ₩970.79B ₩689.08B ₩484.82B ₩189.14B Operating income ₩2.07T ₩1.32T ₩1.11T ₩983.63B ₩537.31B Non-operating income ₩7.29B ₩4.76B ₩13.1B ₩65.69B ₩414.26M Income tax expense ₩504.3B ₩286.74B ₩262.3B ₩210.97B ₩167.69B Net income ₩1.78T ₩1.08T ₩857.69B ₩798.06B ₩393.59B Basic EPS — 15,221.00 12,051.00 11,442.00 5,949.00 Diluted EPS — 15,221.00 12,051.00 11,432.00 —
Balance sheet CONSOLIDATED Line 2025 2024 2023 2022 2021 Total assets ₩11.06T ₩17.34T ₩16.05T ₩16.58T ₩7.97T Current assets ₩4.41T ₩5.52T ₩5.52T ₩6.46T ₩2.82T Cash and equivalents ₩148.85B ₩391.22B ₩367.94B ₩890.82B ₩47.41B Short-term investments ₩1.31T ₩907.35B ₩1.65T ₩2.17T ₩450B Accounts receivable ₩676.47B ₩1.17T ₩679.35B ₩732.84B ₩366.33B Inventory ₩2.13T ₩2.82T ₩2.64T ₩2.38T ₩1.01T Property, plant and equipment ₩6.03T ₩5.37T ₩3.88T ₩3.42T ₩2.21T Total liabilities ₩3.61T ₩6.43T ₩6.22T ₩7.6T ₩2.98T Current liabilities ₩2.53T ₩3.85T ₩4.16T ₩4.18T ₩1.11T Accounts payable ₩486.39B ₩1.51T ₩1.21T ₩1.76T ₩399.03B Short-term debt — — — ₩1.14T ₩159.86B Long-term debt ₩599.01B ₩1.01T ₩239.78B — — Shareholders' equity ₩7.45T ₩10.9T ₩9.83T ₩8.98T ₩4.99T Retained earnings ₩6.87T ₩5.09T ₩4T ₩3.15T ₩2.35T
Cash flow statement CONSOLIDATED Line 2025 2024 2023 2022 2021 Operating cash flow ₩2.25T ₩1.66T ₩1.67T ₩953.05B ₩454.6B Investing cash flow ₩-1.86T ₩-1.24T ₩-1.57T ₩-3.11T ₩-933.49B Financing cash flow ₩-620.5B ₩-433.79B ₩-635.05B ₩3T ₩496.62B Capital expenditure ₩1.39T ₩1.3T ₩995.07B ₩956.84B ₩406.25B Share buybacks ₩92.01B — — — —
Key ratios COMPUTED HERE Line 2025 2024 2023 2022 2021 Gross margin 55.2% 50.4% 48.8% 48.9% 46.3% Operating margin 45.4% 29.0% 30.1% 32.8% 34.3% Net margin 39.2% 23.8% 23.2% 26.6% 25.1% Return on equity 23.9% 9.9% 8.7% 8.9% 7.9% Return on assets 16.1% 6.2% 5.3% 4.8% 4.9% Asset turnover 0.41× 0.26× 0.23× 0.18× 0.20× Current ratio 1.74× 1.43× 1.33× 1.54× 2.55× Debt to equity 48.4% 59.0% 63.2% 84.6% 59.7% Net debt ₩450.16B ₩621.54B ₩-128.15B ₩247.98B ₩112.44B Free cash flow ₩856.07B ₩355.68B ₩671.16B ₩-3.79B ₩48.34B Cash conversion cycle 348d 305d 343d 235d 352d
Amounts are as filed. An em dash means that line was not reported, not that it is nil; rows marked “computed” and the whole key-ratios table are worked out here from those amounts.
About this record 5 fiscal years from 2021 to 2025, covering 29 statement lines, collected from OpenDART. The most recent was confirmed on 2025-12-31.
Its 45.41% operating margin in the latest fiscal year is at or above 89% of the 45 listed companies collected here, closest to Microsoft 46.78% and SK hynix 48.59%.
This page offers no investment view or forecast about Samsung Biologics. The amounts are as the company filed them, the ratios follow from those amounts, and no currency is converted.
Run these figures through the calculators · Reading guides · Methodology